Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03637803
Title MRx0518 and Pembrolizumab Combination Study
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors 4DPharma PLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Kansas Medical Center Kansas City Kansas 66160 United States Details
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 United States Details
Houston Methodist Cancer Center Houston Texas 77030 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Summit Cancer Center Spokane Washington 99208 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field